Avalon Pharmaceuticals Appoints William H. Washecka to Its Board of Directors
February 23 2006 - 7:00AM
PR Newswire (US)
GERMANTOWN, Md., Feb. 23 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (Nasdaq and ArcaEx(R): AVRX), a
biopharmaceutical company focused on the discovery and development
of small molecule therapeutics, today announced the appointment of
William H. Washecka to its board of directors effective March 1,
2006. The addition of Mr. Washecka brings the Avalon Board to nine
members. "We are excited to welcome Bill to the Avalon Board,"
stated Kenneth C. Carter, President and CEO of Avalon
Pharmaceuticals. "He is a proven leader with significant expertise
in finance and business planning and we look forward to his
valuable perspective." "I am very pleased to join the Board of
Avalon Pharmaceuticals, a company with a unique approach to drug
discovery and development," stated Mr. Washecka. About Mr. Washecka
Before joining the pharmaceutical industry, Mr. Washecka spent more
than 30 years working with high-growth technology companies. Bill
Washecka is currently the Chief Financial Officer of Prestwick
Pharmaceuticals, Inc., a manufacturer of drugs for disorders of the
central nervous system. Mr. Washecka has served as Senior Executive
Vice President and Chief Financial Officer at USinternetworking
Inc, a publicly held application service provider. He has also held
the position of Senior Partner at Ernst & Young, where he
established and managed the high technology and emerging business
practice in the Mid-Atlantic area. Additionally, Mr. Washecka was a
co-founder of the Mid-Atlantic Venture Capital Conference. Mr.
Washecka holds a BS in accounting from Bernard Baruch College of
New York and participated in Kellogg Advanced Management Program.
He is a CPA in Maryland, Virginia, the District of Columbia and New
York. About Avalon Pharmaceuticals, Inc. Avalon Pharmaceuticals is
a biopharmaceutical company focused on the discovery and
development of small molecule therapeutics. Avalon seeks to
discover and develop novel therapeutics through the use of a
comprehensive, innovative and proprietary suite of technologies
based upon large-scale gene expression analysis, which it calls
AvalonRx(R). Avalon Pharmaceuticals was established in 1999 and is
headquartered in Germantown, Maryland. Contacts: Avalon
Pharmaceuticals, Inc. Gary Lessing Executive Vice President and CFO
Tel: (301) 556-9900 Fax: (301) 556-9910 Email: Noonan Russo Wendy
Lau (Media) Tel: (212) 845-4272 Jane Petrino (Investors) Tel: (212)
845-4274 DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: Gary
Lessing, Executive Vice President and CFO of Avalon
Pharmaceuticals, Inc., +1-301-556-9900, +1-301-556-9910, ; or
Media: Wendy Lau, +1-212-845-4272, or Investors: Jane Petrino,
+1-212-845-4274, both of Noonan Russo, both for Avalon
Pharmaceuticals, Inc.
Copyright